FDA approves biologic for treating psoriasis in those as young as 12

| Joe Doolen

Adolescents with moderate to severe plaque psoriasis have a new option for treatment. On Oct. 13, 2017, the U.S. Food and Drug Administration (FDA) approved the use of Stelara (ustekinumab) for treating psoriasis in youth ages 12 and older. 

Stelara is a biologic (a drug made in a lab from living cells) that blocks proteins interleukin-12 and interleukin-23 from attaching to other cells, thus preventing an undesired inflammatory response – raised, red patches of skin that are often itchy and painful. Stelara is administered in two initial injections followed by an additional injection every 12 weeks, the fewest doses of any biologic option for plaque psoriasis treatment. Adolescents also must be candidates for phototherapy (skin exposure to UV light) or systemic therapy (pills or injections).

This new approval affects a crucial age group among those with plaque psoriasis, roughly one-third of whom develop the disease before age 20. In adolescents, psoriasis commonly affects the face and scalp. 

In a Phase 3 clinical trial, two-thirds of adolescents receiving injections at week 0 and week 4 showed total clearance or minimal coverage of psoriasis at week 12. Treatment involves injections every 12 weeks after the initial two. Safety findings in adolescents were consistent with those of adults.

Stelara, manufactured by Janssen, has been FDA-approved for treating adults with psoriasis and/or psoriatic arthritis since 2009.

 


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Never mind an endless series of debates. Meet Matt Mercier, one of our three...
PPI
NPF has embarked on the Psoriasis Prevention Initiative– a multi-disciplinary,...
Tami Seretti is one of three individuals who have distinguished themselves with...
The 2019 NPF annual survey is your opportunity to share your data and help...
Facebook fundraiser
It’s easy to start supporting NPF research with your own personal fundraising...
Data collection alone won't find us a cure for psoriatic disease. First we...
The best treatment starts with a team of medical professionals who are up-to-...
NPF board of directors member Richard Seiden shares his notes.
Kory Schrom, M.D.
Researcher Kory Schrom’s interest in the microbiome may answer this and other...